1. Market Research
  2. > Healthcare Market Trends
  3. > Healthcare Analysis & Statistics, September 2019

Healthcare Analysis & Statistics, September 2019

1-30 of about 300 reports

Trogarzo

Trogarzo

  • $ 10000
  • Industry report
  • July 2019

Trogarzo (ibalizumab; Theratechnologies/TaiMed Biologics) is a recombinant humanized monoclonal antibody approved for the treatment of HIV-1 infection. It targets the HIV-1 post-attachment process by binding ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical, Therapy
  • Countries : United States
Cilofexor

Cilofexor

  • $ 10000
  • Industry report
  • July 2019

Cilofexor (Gilead), a nonsteroidal FXR agonist, is a ligand-activated nuclear hormone receptor that is a key regulator of bile acid synthesis, conjugation, and excretion. It is abundant in the liver, gallbladder, ...

  • Industries : Healthcare
Tropifexor

Tropifexor

  • $ 10000
  • Industry report
  • July 2019

FXR is a nuclear receptor that regulates bile acid metabolism and signaling. Activation of the receptor inhibits bile acid synthesis from cholesterol via cytochrome P450 7A1 and increases bile acid conjugation, ...

  • Industries : Mental Health, Pathology
Elafibranor

Elafibranor

  • $ 10000
  • Industry report
  • July 2019

Elafibranor (Genfit) is an oral peroxisome proliferator-activated receptor (PPAR) alpha-delta dual agonist. The medication activates PPAR-alpha and PPAR-delta, which control gene expression. Stimulating ...

  • Industries : Healthcare
  • Countries : United States, European Union
Emricasan

Emricasan

  • $ 10000
  • Industry report
  • July 2019

Emricasan (Conatus/Novartis) is a small molecule which inhibits pan-caspases. These enzymes are key modulators of apoptosis and inflammation, and chronically elevated apoptosis is often present in live ...

  • Industries : Pathology
Aramchol

Aramchol

  • $ 10000
  • Industry report
  • July 2019

Aramchol (arachidyl amido cholanoic acid; Galmed) is a conjugate of cholic acid and arachidic acid, and belongs to the synthetic fatty acid bile acid conjugates (FABACs) family. Aramchol inhibits the live ...

  • Industries : Healthcare
  • Countries : United States, European Union
Cenicriviroc

Cenicriviroc

  • $ 10000
  • Industry report
  • July 2019

Cenicriviroc (Allergan/Takeda) is a potent immunomodulator that blocks the chemokine receptors-2/5 (CCR-2/5). CCR-2/5 have been linked to the inflammatory and fibrogenic pathways in non-alcoholic steatohepatitis ...

  • Industries : Healthcare
  • Countries : United States, European Union
Firsocostat

Firsocostat

  • $ 10000
  • Industry report
  • July 2019

Firsocostat (Gilead) is an acetyl-CoA carboxylase (ACC) allosteric inhibitor which binds to the biotin carboxylase domain of ACC with high potency and selectivity. Firsocostat inhibits both isoforms (ACC1 ...

  • Industries : Healthcare
Selonsertib

Selonsertib

  • $ 10000
  • Industry report
  • July 2019

Selonsertib (Gilead) is a small molecule that inhibits apoptosis signal-regulating kinase 1 (ASK1). ASK1 has been shown to promote inflammation, apoptosis, and fibrosis in settings of oxidative stress. ...

  • Industries : Healthcare
Juluca

Juluca

  • $ 10000
  • Industry report
  • June 2019

Juluca ([dolutegravir + rilpivirine]; ViiV Healthcare/Johnson and Johnson) is a single-tablet regimen approved in the US for the treatment of patients infected with HIV-1 who have achieved viral supp ...

  • Industries : Therapy
  • Countries : United States, European Union
Complera

Complera

  • $ 10000
  • Industry report
  • June 2019

Complera (rilpivirine/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Johnson and Johnson) is a single-tablet regimen for the treatment of HIV-1 infection.

  • Industries : Therapy
  • Countries : United States, European Union
Atripla

Atripla

  • $ 10000
  • Industry report
  • June 2019

Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Bristol-Myers Squibb) is a single-tablet regimen approved for the treatment of HIV-1 infection.

  • Industries : Therapy
  • Countries : United States, European Union
Genvoya

Genvoya

  • $ 10000
  • Industry report
  • June 2019

Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate [TAF]; Gilead) is a single-tablet regimen (STR) approved for the treatment of HIV-1 infection.

  • Industries : Therapy
  • Countries : United States, European Union
Stribild

Stribild

  • $ 10000
  • Industry report
  • June 2019

Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Japan Tobacco) is a single-tablet regimen for the treatment of HIV-1 infection. It is a co-formulation of marketed ...

  • Industries : Therapy
  • Countries : United States, European Union, Japan
Tivicay

Tivicay

  • $ 10000
  • Industry report
  • June 2019

Tivicay (dolutegravir; ViiV Healthcare) is a once-daily, unboosted integrase inhibitor (INI) for the treatment of HIV-1 infection.

  • Industries : Therapy
  • Countries : United States, European Union
Isentress

Isentress

  • $ 10000
  • Industry report
  • June 2019

Isentress (raltegravir; Merck and Co) is a twice-daily, unboosted integrase inhibitor (INI) that is used in combination with other antiretroviral drugs for treatment of HIV-1 infection.

  • Industries : Therapy
  • Countries : United States, European Union
leronlimab

leronlimab

  • $ 10000
  • Industry report
  • June 2019

Leronlimab (CytoDyn) is a humanized monoclonal antibody directed against C-C chemokine receptor 5 (CCR5), which is a co-receptor required for the attachment and entry of CCR5-tropic HIV-1 viruses into ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, European Union
Dovato

Dovato

  • $ 10000
  • Industry report
  • June 2019

Dovato ([dolutegravir + lamivudine]; ViiV Healthcare) is a single-tablet regimen approved in the US for the treatment of HIV-1 infection in patients who are treatment-naïve. It is also being developed ...

  • Industries : Therapy
  • Countries : United States, European Union
fostemsavir

fostemsavir

  • $ 10000
  • Industry report
  • June 2019

Fostemsavir (GSK3684934) (ViiV Healthcare), previously known as BMS-663068, is an oral prodrug of GSK2616713 (formerly BMS-626529). It is an attachment inhibitor which binds to the gp120 protein of HIV ...

  • Industries : Healthcare
Prostate Cancer Diagnostics and Minimally Invasive Treatments Market

Prostate Cancer Diagnostics and Minimally Invasive Treatments Market

  • $ 4750
  • Industry report
  • July 2019

This report includes a discussion of leading products, new technologies, market forecasts, drivers and limiters, competitors, trends and opportunities in the nearly $1bn Prostate Cancer Diagnostics and ...

  • Industries : Cancer, Pathology, Diagnostics
  • Countries : United States, Japan
Interventional Cardiology: Implantable Cardioverter Defibrillators

Interventional Cardiology: Implantable Cardioverter Defibrillators

  • $ 4750
  • Industry report
  • July 2019

This comprehensive medical market and technology report provides an overview and in-depth market analysis of implantable cardioverter defibrillators (ICDs) used to treat forms of cardiac arrhythmia and ...

  • Industries : Patient Monitoring
  • Countries : World
Market Spotlight: Fibromyalgia

Market Spotlight: Fibromyalgia

  • $ 1318
  • Industry report
  • July 2019

This Market Spotlight report covers the Fibromyalgia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, patent ...

  • Industries : Chronic Disease, Pathology
  • Countries : United States, World
Market Spotlight: NHL: Peripheral T-cell lymphoma (PTCL)

Market Spotlight: NHL: Peripheral T-cell lymphoma (PTCL)

  • $ 1318
  • Industry report
  • July 2019

This Market Spotlight report covers the Peripheral T-Cell Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, patent information, a 10-year disease incidence ...

  • Industries : Cancer
Market Spotlight: Glioblastoma

Market Spotlight: Glioblastoma

  • $ 1318
  • Industry report
  • June 2019

This Market Spotlight report covers the Glioblastoma market, comprising key marketed and pipeline drugs, clinical trials, patent information, a 10-year disease incidence forecast, and licensing and acquisition ...

  • Industries : Cancer, Pathology
  • Countries : United States
Rheumatoid Arthritis KOL Interview – UK

Rheumatoid Arthritis KOL Interview – UK

  • $ 599
  • Industry report
  • July 2019

A UK-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies fo ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United Kingdom
Rheumatoid Arthritis KOL Interview – California, US

Rheumatoid Arthritis KOL Interview – California, US

  • $ 599
  • Industry report
  • July 2019

A US-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies fo ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States
Rheumatoid Arthritis KOL Interview – New Jersey, US

Rheumatoid Arthritis KOL Interview – New Jersey, US

  • $ 599
  • Industry report
  • July 2019

A US-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies fo ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States
Bladder Cancer KOL Interview – US

Bladder Cancer KOL Interview – US

  • $ 599
  • Industry report
  • May 2019

A US KOL provides insight into the current treatment landscape for bladder cancer. Critical unmet needs in the bladder cancer market along with future trends are also discussed.

  • Industries : Cancer, Pathology
  • Countries : United States
Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – France

Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – France

  • $ 599
  • Industry report
  • May 2019

This interview with a French key opinion leader (KOL) provides insight into pipeline therapies for non-alcoholic steatohepatitis (NASH), as well as pricing strategies and future treatment rates for the ...

  • Industries : Healthcare
  • Countries : France
Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US, Reimbursement

Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US, Reimbursement

  • $ 599
  • Industry report
  • May 2019

This reimbursement interview with a US key opinion leader (KOL) provides insight into pricing strategies, pricing barriers, and potential reimbursement criteria for non-alcoholic steatohepatitis thera ...

  • Industries : Healthcare
  • Countries : United States
About 283000 reports

Download Unlimited Documents from Trusted Public Sources

Investor Report, September 2019

  • September 2019
    40 pages
  • Healthcare  

View report >

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on